LENZ Therapeutics (LENZ) Operating Income (2020 - 2026)
LENZ Therapeutics (LENZ) reported Operating Income of -$44.1 million for Q1 2026, down 160.68% year-over-year from $72.7 million in Q1 2025, and down 14.75% on a QoQ basis from -$38.5 million in Q4 2025.
LENZ Therapeutics (LENZ) has 7 years of Operating Income data on file, last reported at -$44.1 million in Q1 2026.
- Quarterly Operating Income fell 160.68% year-over-year to -$44.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$118.3 million (down 99.05% YoY) and the FY2025 annual result came in at -$91.1 million, down 55.5% from the prior year.
- Operating Income slipped to -$44.1 million in Q1 2026 per LENZ's latest filing, from -$38.5 million in the prior quarter.
- Across five years, Operating Income topped out at -$12.6 million in Q1 2023 and bottomed at -$44.1 million in Q1 2026.
- The 5-year median for Operating Income is -$18.9 million (2025), against an average of -$21.9 million.
- The widest annual swing landed in 2022, when Operating Income slumped 177.09%; it then soared 51.4% in 2023.
- Tracing LENZ's Operating Income over 5 years: stood at -$26.8 million in 2022, then increased by 6.59% to -$25.0 million in 2023, then soared by 39.07% to -$15.2 million in 2024, then plunged by 152.63% to -$38.5 million in 2025, then declined by 14.75% to -$44.1 million in 2026.
- Per Business Quant, the three latest LENZ Operating Income figures stand at -$44.1 million (Q1 2026), -$38.5 million (Q4 2025), and -$18.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.97 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -19.70 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.76 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.14 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.82 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 642.90 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 268.64 Mn |
| 10 | LENZ Therapeutics | 235.77 Mn | 235.77 Mn | 825,000.00 | -44.14 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -44.14 Mn |
| Dec 31, 2025 | -38.46 Mn |
| Sep 30, 2025 | -18.89 Mn |
| Jun 30, 2025 | -16.86 Mn |
| Mar 31, 2025 | -16.93 Mn |
| Dec 31, 2024 | -15.23 Mn |
| Sep 30, 2024 | -12.95 Mn |
| Jun 30, 2024 | -14.35 Mn |
| Mar 31, 2024 | -16.09 Mn |
| Dec 31, 2023 | -24.99 Mn |
| Sep 30, 2023 | -19.87 Mn |
| Jun 30, 2023 | -14.96 Mn |
| Mar 31, 2023 | -12.62 Mn |
| Dec 31, 2022 | -26.75 Mn |
| Sep 30, 2022 | -26.15 Mn |
| Jun 30, 2022 | -26.78 Mn |
| Mar 31, 2022 | -25.96 Mn |
| Dec 31, 2021 | -18.94 Mn |
| Sep 30, 2021 | -14.60 Mn |
| Jun 30, 2021 | -17.53 Mn |
| Mar 31, 2021 | -9.37 Mn |
| Dec 31, 2020 | -8.32 Mn |
| Sep 30, 2020 | -3.76 Mn |
| Jun 30, 2020 | -1.29 Mn |